公开(公告)号：US12187722B2

公开(公告)日：2025-01-07

申请号：US17439735

申请日：2020-03-13

Applicant: The General Hospital Corporation

Inventor： Xu Wu ,  Pranab Maiti ,  Chandrasekhar Abbineni ,  Krishna Chaitanya Talluri ,  Sunil Kumar Panigrahi ,  Gopala Krishna Jarugumilli ,  Yang Sun

IPC: A61P35/00 ,  A61K31/165 ,  A61K31/18 ,  A61K31/195 ,  A61K31/196 ,  A61K31/24 ,  A61K31/397 ,  A61K31/401 ,  A61K31/405 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/428 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/4704 ,  A61K31/496 ,  A61K31/4965 ,  C07C211/26 ,  C07C211/55 ,  C07C211/56 ,  C07C211/60 ,  C07C225/22 ,  C07C229/44 ,  C07C229/48 ,  C07C229/58 ,  C07C237/40 ,  C07C255/58 ,  C07C311/44 ,  C07C317/28 ,  C07C323/63 ,  C07D205/04 ,  C07D207/16 ,  C07D207/34 ,  C07D209/08 ,  C07D211/62 ,  C07D213/74 ,  C07D213/79 ,  C07D213/80 ,  C07D215/227 ,  C07D231/14 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D235/06 ,  C07D235/08 ,  C07D235/18 ,  C07D239/42 ,  C07D239/48 ,  C07D239/88 ,  C07D241/20 ,  C07D241/28 ,  C07D249/08 ,  C07D249/10 ,  C07D257/04 ,  C07D275/06 ,  C07D277/28 ,  C07D295/135 ,  C07D295/155 ,  C07D317/32 ,  C07D401/06 ,  C07D401/12 ,  C07D471/04

Abstract: The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

公开(公告)号：US20240294465A1

公开(公告)日：2024-09-05

申请号：US18567733

申请日：2022-06-09

Applicant: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT

Inventor： Gerald BURGSTALLER ,  Michael GERCKENS ,  Oliver PLETTENBURG ,  Ali YILDIRIM ,  Ma HUILONG

IPC: C07C235/38 ,  A61K31/167 ,  A61K31/245 ,  A61K31/343 ,  A61K31/353 ,  A61K31/357 ,  A61K31/36 ,  A61K31/37 ,  A61K31/396 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/4245 ,  A61K31/44 ,  A61K31/4402 ,  C07C317/32 ,  C07C325/02 ,  C07D209/08 ,  C07D213/643 ,  C07D213/75 ,  C07D229/02 ,  C07D231/20 ,  C07D235/08 ,  C07D249/04 ,  C07D271/12 ,  C07D307/81 ,  C07D307/87 ,  C07D311/20 ,  C07D311/58 ,  C07D317/60 ,  C07D319/18 ,  G01N33/50 ,  G01N33/58

CPC classification number: C07C235/38 ,  A61K31/167 ,  A61K31/245 ,  A61K31/343 ,  A61K31/353 ,  A61K31/357 ,  A61K31/36 ,  A61K31/37 ,  A61K31/396 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/4245 ,  A61K31/44 ,  A61K31/4402 ,  C07C317/32 ,  C07C325/02 ,  C07D209/08 ,  C07D213/643 ,  C07D213/75 ,  C07D229/02 ,  C07D231/20 ,  C07D235/08 ,  C07D249/04 ,  C07D271/12 ,  C07D307/81 ,  C07D307/87 ,  C07D311/20 ,  C07D311/58 ,  C07D317/60 ,  C07D319/18 ,  G01N33/5044 ,  G01N33/582 ,  C07C2601/02

Abstract: The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever and pericarditis. Further, the invention relates to a pharmaceutical composition comprising said cinnamic acid amides and to a screening essay for identifying compounds suitable for the treatment of fibrosis.

公开(公告)号：US20240132467A1

公开(公告)日：2024-04-25

申请号：US18332551

申请日：2023-06-09

Applicant: TMEM16A Limited

Inventor： Stephen COLLINGWOOD ,  Jonathan David Hargrave ,  Duncan Alexander Hay ,  Clive McCarthy ,  Thomas Beauregard Schofield ,  Edward Walker ,  Naomi Went

IPC: C07D401/06 ,  A61P11/12 ,  C07D235/08 ,  C07D235/12 ,  C07D235/16 ,  C07D405/04 ,  C07D413/06

CPC classification number: C07D401/06 ,  A61P11/12 ,  C07D235/08 ,  C07D235/12 ,  C07D235/16 ,  C07D405/04 ,  C07D413/06

Abstract: Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

公开(公告)号：US11787770B2

公开(公告)日：2023-10-17

申请号：US17323290

申请日：2021-05-18

Applicant: Purdue Research Foundation

Inventor： Robert Graham Cooks ,  Pallab Basuri ,  Nicolás M. Morato ,  Thalappil Pradeep

IPC: C07D235/08

CPC classification number: C07D235/08

Abstract: The invention generally relates to methods of coupling a carbon containing moiety to an amine containing moiety.

公开(公告)号：US20230295140A1

公开(公告)日：2023-09-21

申请号：US18201715

申请日：2023-05-24

Applicant: Acucela Inc.

Inventor： Mark W. ORME ,  Edison S. ZUNIGA ,  Vladimir A. KUKSA ,  Russell Stuart CRAFT ,  Eduardo Moreno SAVEEDRA ,  Johannes Wilhelm Georg MEISSNER ,  Jacobus Antonius Joseph den HARTOG ,  Albert Cornelis DROS

IPC: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

CPC classification number: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

Abstract: Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

公开(公告)号：US11738009B2

公开(公告)日：2023-08-29

申请号：US16605408

申请日：2018-04-17

Applicant: TEMPEST THERAPEUTICS, INC.

Inventor： Yalda Bravo ,  Jason David Burch ,  Austin Chih-Yu Chen ,  Joe Fred Nagamizo

IPC: A61K31/437 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K39/395 ,  C07D209/08 ,  C07D231/56 ,  C07D235/06 ,  C07D403/12 ,  C07D413/10 ,  C07D471/04 ,  A61P35/00 ,  C07D209/18 ,  C07D235/08 ,  C07K16/28

CPC classification number: A61K31/437 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K39/3955 ,  A61P35/00 ,  C07D209/08 ,  C07D209/18 ,  C07D231/56 ,  C07D235/06 ,  C07D235/08 ,  C07D403/12 ,  C07D413/10 ,  C07D471/04 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

公开(公告)号：US20230257356A1

公开(公告)日：2023-08-17

申请号：US17922827

申请日：2021-05-14

Applicant: LG CHEM, LTD.

Inventor： Miyeon HAN ,  Sung Kil HONG ,  Dong Uk HEO ,  Jung Min YOON ,  Heekyung YUN

IPC: C07D235/08 ,  H10K85/60 ,  C07D401/14 ,  C07D409/04 ,  C07D403/10 ,  C07D403/04 ,  C07D405/04

CPC classification number: C07D235/08 ,  H10K85/6572 ,  H10K85/615 ,  C07D401/14 ,  H10K85/654 ,  H10K85/622 ,  H10K85/6576 ,  C07D409/04 ,  C07D403/10 ,  C07D403/04 ,  C07D405/04 ,  H10K85/6574

Abstract: Provided is a benzimidazole-substituted fluoranthene compound of Chemical Formula 1:




where the substituents are as described in the specification, and an organic light emitting device including the same.

公开(公告)号：US20230242529A1

公开(公告)日：2023-08-03

申请号：US18170022

申请日：2023-02-16

Applicant: FIMECS, Inc.

Inventor： Yusuke TOMINARI ,  Yoshihide TOMATA ,  Kanae GAMO ,  Naomi KITAMOTO

IPC: C07D471/04 ,  C07D209/08 ,  C07D209/42 ,  C07D231/14 ,  C07D231/56 ,  C07D235/08 ,  C07D403/06 ,  C07D403/12 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/08 ,  C07D495/14

CPC classification number: C07D471/04 ,  C07D209/08 ,  C07D209/42 ,  C07D231/14 ,  C07D231/56 ,  C07D235/08 ,  C07D403/06 ,  C07D403/12 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/08 ,  C07D495/14

Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.

公开(公告)号：US20230159446A1

公开(公告)日：2023-05-25

申请号：US18088447

申请日：2022-12-23

Applicant: NANJING IMMUNOPHAGE BIOTECH CO., LTD.

Inventor： Guohuang FAN ,  Hongyu YANG ,  Kin Chiu FONG ,  Jianfei WANG

IPC: C07C311/46 ,  C07D211/12 ,  C07D211/14 ,  C07D215/36 ,  C07D241/44 ,  C07D239/93 ,  C07D209/48 ,  C07D239/42 ,  C07D235/08 ,  C07D401/12 ,  C07D231/56

CPC classification number: C07C311/46 ,  C07D211/12 ,  C07D211/14 ,  C07D215/36 ,  C07D241/44 ,  C07D239/93 ,  C07D209/48 ,  C07D239/42 ,  C07D235/08 ,  C07D401/12 ,  C07D231/56

Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

公开(公告)号：US20220380387A1

公开(公告)日：2022-12-01

申请号：US17764778

申请日：2021-01-22

Applicant: IDEMITSU KOSAN CO.,LTD.

Inventor： Takushi SHIOMI ,  Keiichi YASUKAWA ,  Hiromi NAKANO ,  Toshinari OGIWARA

IPC: C07F5/02 ,  C07D493/04 ,  C07C211/54 ,  C07C15/20 ,  C07D209/82 ,  C07D405/10 ,  C07D491/048 ,  C07D409/10 ,  C07D405/14 ,  C07F7/08 ,  C07D403/14 ,  C07D409/14 ,  C07D487/04 ,  C07D471/04 ,  C07D409/04 ,  C07D401/14 ,  C07D251/24 ,  C07D403/04 ,  C07D403/10 ,  C07D333/76 ,  C07D307/91 ,  C07D235/08 ,  C07F9/53 ,  C07C13/72 ,  C07D519/00 ,  C07D487/14 ,  C07D495/04 ,  C07C15/38 ,  C07D413/10 ,  C07D491/147 ,  C07D413/14 ,  C07D495/14 ,  C07D401/04 ,  C07D487/16 ,  C07D241/46 ,  H01L51/00 ,  H01L51/50

Abstract: An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S1(M2) of the compound M2 and a singlet energy S1(M3) of the compound M3 satisfy the relationship S1(M3)>S1(M2).